肿瘤细胞治疗研究
英文原题：Successful treatment of a case with synchronous follicular lymphoma and gastric adenocarcinoma with CD19 CAR T cells and literature review.
已知和目的：抗CD19 CAR-T细胞疗法对B细胞淋巴瘤有效。
已知和目的：抗CD19 CAR-T细胞疗法对B细胞淋巴瘤有效。然而，它很少用于淋巴瘤合并其他恶性肿瘤的情况。病例描述：一名复发/难治性滤泡性淋巴瘤（r/r FL）患者接受了抗CD19 CAR-T细胞疗法，并实现了淋巴瘤的完全缓解。然而，在细胞治疗期间被诊断为胃腺癌（GAC）。输注CAR-T细胞后，他接受了GAC的根治性治疗，治疗后r/r FL和GAC均维持完全缓解。新发现和结论：抗CD19 CAR-T疗法是r/r FL的有效治疗手段，也为GAC的序贯治疗提供了机会，并且此后仍保持了显著的生活质量。
WHAT IS KNOWN AND OBJECTIVE: Anti-CD19 CAR-T cell therapy is effective in B-cell lymphoma. However, it is rarely used in lymphoma combined with other malignant tumours. CASE DESCRIPTION: A relapsed/refractory follicular lymphoma (r/r FL) patient underwent anti-CD19 CAR-T cell therapy and achieved complete response to lymphoma. However, gastric adenocarcinoma (GAC) was diagnosed during the cellular therapy. After infusion of CAR-T cells, he received curative treatment for GAC, and maitained complete response in both r/r FL and GAC after the treatment. WHAT IS NEW AND CONCLUSION: Anti-CD19 CAR-T therapy is an effective treatment for r/r FL, also provided opportunity for the sequential therapy of GAC, and remained significant quality of life afterwards.
MEMBER ACCOUNT
登录成功会直接打开下一页。
